DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...

DexCom Inc. closed 29.14% below its 52-week high of $93.25, which the company achieved on February 18th.

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them.

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...

Fintel reports that on October 1, 2025, Goldman Sachs maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

The company will unveil Dexcom Smart Basal, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for ...

Shares of DexCom Inc. DXCM shed 3.06% to $76.00 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.30% to 6,532.04 and the ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...